Quantbot Technologies LP Invests in Natera,
February 10, 2023
Trending News 🌥️
Quantbot Technologies LP has recently announced its investment in Natera ($NASDAQ:NTRA), Inc., a biotechnology company focused on developing and commercialising clinical genetic tests. Natera’s mission is to empower clinicians and patients with innovative clinical testing technology and services. Natera’s primary products are non-invasive prenatal tests that can determine paternity, diagnose chromosomal abnormalities in pregnancies, and test for inherited genetic conditions. The company also provides reproductive health testing such as preimplantation genetic testing and cancer screening services. Natera’s technology platform includes proprietary sample and bioinformatics processing technologies and analytic software.
Additionally, the company uses genetic testing to support clinical research studies. Quantbot Technologies LP is an alternative asset manager that specializes in quantitative trading strategies. The company’s focus is on utilizing systematic trading and quantitative analysis to identify attractive investment opportunities. Quantbot Technologies LP has a long-term view of investments, which could benefit Natera’s growth prospects. The investment is a sign of confidence in Natera’s business model and its ability to capitalize on new opportunities in the biotechnology sector. Natera’s stock has seen a surge in its price since Quantbot Technologies LP made their investment. Investors should keep a close eye on Natera as it begins to capitalize on the investment and make strides towards becoming a leader in the biotechnology sector.
Share Price
On Thursday, Natera, Inc. saw a slight increase in its stock prices after a major investor, Quantbot Technologies LP, announced their investment in the company. Natera’s stock opened that day at $44.2 and closed the trading day at $44.0, up by 0.3% from the previous closing price of $43.9. This announcement has caused many investors to take a closer look at Natera, which is a biotechnology company focused on developing products and services to diagnose genetic disorders and other conditions. The company is also developing molecular diagnostics to detect cancer and predict disease risk as well as technologies to assist with infertility treatments. In addition to their current offerings, Natera continues to explore new opportunities in the healthcare industry. Quantbot Technologies LP’s investment in Natera is certainly a positive sign for the company and the biotechnology industry in general.
The investment will give Natera the capital they need to continue to grow and develop their products and services, which could lead to further advances in the medical field. The investment could also have a trickle-down effect, as other investors may be more likely to invest in Natera and other biotechnology companies as a result of Quantbot Technologies LP’s decision to do so. Overall, the investment by Quantbot Technologies LP in Natera is an exciting development for the biotechnology industry and an indication that there is room for growth in the field. In addition to the potential benefits to Natera, this investment could help boost the entire industry, which could lead to even more groundbreaking discoveries in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 776 | -545.79 | -70.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -449.11 | 387.93 | 22.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.01k | 647.49 | 3.72 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.5% | – | -69.2% |
| FCF Margin | ROE | ROA |
| -63.7% | -83.2% | -33.2% |
Analysis
Based on GoodWhale’s financial analysis, NATERA is classified as a medium risk investment, with four risk warnings identified in the income sheet, balance sheet, cashflow statement and non financial areas. GoodWhale’s analysis brings to the table an extensive set of financial parameters and metrics to provide a comprehensive assessment of the company’s financial health. The comprehensive evaluation of NATERA’s financial state assesses the company from multiple angles, including assessing the company’s financial performance, liquidity, efficiency, profitability and debt levels. GoodWhale’s in-depth analysis covers all key aspects of the company’s financials to provide a clear understanding of the company’s overall risk profile. Additionally, GoodWhale’s analysis provides a detailed overview of the company’s business operations, allowing investors to make informed decisions. GoodWhale’s financial analysis includes an evaluation of the company’s income sheet, balance sheet and cash flow statement, highlighting potential risks. The assessment of the company’s non-financial performance further adds to understanding the company’s overall risk profile. GoodWhale’s financial analysis provides investors with an in depth understanding of NATERA’s financial state, allowing for more informed decision making. Registering on goodwhale.com will provide an opportunity to access all risk warnings detected by GoodWhale in NATERA’s financials and assess them in detail. More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
Natera, Inc., a diagnostics company, has recently attracted the attention of Quantbot Technologies LP, a quantitative investment management firm. Quantbot has decided to invest in Natera, indicating confidence in the company’s potential and its value as an investment. Through their analysis, Quantbot has determined that Natera is a strong investment opportunity with promising growth potential.
They have identified the company’s competitive advantages, such as its advanced technology and innovative products, as key factors in establishing the company as a reliable long-term investment. The firm has also assessed Natera’s financials, business model, and market position, and believes that the company is well-positioned for success.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
